A significantly higher proportion of DUPIXENT patients achieved meaningful itch
improvement at Week 24 in PRIME (primary endpoint)1,3

PRIME

Proportion of patients with ≥4-point improvement in WI-NRS at Week 241-3,a

  • A nominal difference was observed at Week 4 (19% with DUPIXENT vs 4% with placebo)3

PRIME2

  • A nominal difference was observed at Week 11 (33% with DUPIXENT vs 17% with placebo), with a significantly greater proportion of DUPIXENT patients achieving a meaningful response at Week 12 (37% with DUPIXENT vs 22% with placebo; P=0.022, primary endpoint). At Week 24, 58% of DUPIXENT patients achieved significant itch relief vs 20% with placebo (P<0.001, secondary endpoint)1-3
POOLED ANALYSIS:
PRIME AND PRIME2
Itch improvement observed after first dose (as measured at Week 2)4
7.9%

of DUPIXENT patients had ≥4-point improvement in WI-NRS at Week 2 vs 1.9% with placebo3,4

59%

of DUPIXENT patients had ≥4-point improvement in WI-NRS at Week 24 vs 19% with placebo3,4

Definitive conclusions cannot be made for these results as the data were not multiplicity controlled and P values were nominal.

DUPIXENT showed
consistent efficacy
regardless of patients’
atopic background1,5

POOLED ANALYSIS:
PRIME AND PRIME2

Itch improvement regardless of patients’ history of atopy1,5

Definitive conclusions cannot be made for these results as the data were not
multiplicity controlled and P values were nominal.

In the PRIME trials, patients were stratified by their history of atopy.

57%
of patients across PRIME and PRIME2 did not have a history of atopy (defined as having a medical history of atopic dermatitis, allergic rhinitis/rhinoconjunctivitis, asthma, or food allergy)1

Explore NODULE CLEARANCE

VIEW IGA PN-S RESULTS

IGA PN-S, Investigator’s Global Assessment PN-Stage; Q2W, once every 2 weeks; SD, standard deviation; WI-NRS, Worst Itch numerical rating scale.